Mizuho upgraded Atara Biotherapeutics to Outperform from Neutral with an $18 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Atara Biotherapeutics Announces CEO Transition and New Leadership Compensation
- Atara sees FY24 OpEx down roughly 35% year-over-year
- Atara Biotherapeutics reports Q2 EPS ($3.10), consensus ($1.56)
- Atara Biotherapeutics Inc (ATRA) Q2 Earnings Cheat Sheet
- Biotech Alert: Searches spiking for these stocks today